Zydus receives market authorisation for Morphine Sulfate ER Tablets

To be manufactured at Nesher Pharmaceuticals, USA

Cadila Healthcare announced that the Zydus group has received the market authorisation from the USFDA to market Morphine Sulfate ER Tablets. The product used in the treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals, USA.

Powered by Capital Market - Live News